Drugs / Abametapir
Abametapir
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | XEGLYZE | — | 2020-07-24 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02061813 | Jan 2014 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01518699 | Jan → May 2012 | lice infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02010333 | Apr 2013 → Jul 2014 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 2 | NCT01336647 | Apr → Aug 2011 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02062073 Comparator | Jan → Mar 2014 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02097485 Comparator | May → Sep 2014 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02060903 Comparator | Feb → Jul 2014 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 3 | NCT02062060 Comparator | Feb → Jul 2014 | Pediculus humanus capitis infestation | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abametapir | “This study was a randomized, double-blind, placebo- and active-controlled, crossover study that evaluated the potential of Abametapir to prolong cardiac repolarization in...” NCT01518699 ↗6“HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.” NCT02010333 ↗ |
| Known as | 5,5'-dimethyl-2,2'-dipyridyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2205807 ↗ |
| Known as | 6,6'-bi-3-picoline | ChEMBL registry synonym — accepted as the source's own label CHEMBL2205807 ↗ |
| Known as | Ha44 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01336647 ↗ |
| Known as | Xeglyze | ChEMBL registry synonym — accepted as the source's own label CHEMBL2205807 ↗ |
| Modality | Small molecule | — CHEMBL2205807 ↗ |
| Route | Topical | “Administered topically” NCT01336647 ↗ |